ML20006B583

From kanterella
Jump to navigation Jump to search
Ack Receipt of Re Constituent Anderson Ltr Supporting Petition for Rulemaking to Revise 10CFR35.NRC Reexamining Regulations Governing Use of Radiopharms in Nuclear Medicine.Comments Will Be Taken Into Consideration
ML20006B583
Person / Time
Issue date: 01/17/1990
From: Rathbun D
NRC OFFICE OF GOVERNMENTAL & PUBLIC AFFAIRS (GPA)
To: Duncan J
HOUSE OF REP.
Shared Package
ML20006B584 List:
References
RULE-PRM-35-9 CCS, NUDOCS 9002050103
Download: ML20006B583 (2)


Text

.

]

us

'1 o

UNITED STATES -

Il

~g-d

.8

' NUCLEAR REGULATORY COMMISSION.

o

{

I wAsmarow, o. c.nomes

%.,,,, +,1

.a January 17, 1990 i

The Honorable John J. Duncan, Jr.

United States House of Representatives Washington, D.

C.'

20515-

Dear Congressman Duncan:

1 L

This is to acknowledge receipt of your letter dated January 3,1990, U

transmitting correspondence from your constituent, Shannon Anderson ;

in support of a petition for rulemaking-to revise 10 CFR 35 Regulations.-

The petition for.rulemaking was submitted.to the Nuclear Regulatory l

Consiission (NRC) by the American College of Nuclear Physicians and the.

Society of Nuclear Medicine.. The petitioners requested that.the NRC modify current regulations ~ to allow:

(a)-the use.of radiopharmaceuticals for therapeutic indications not listed in the package insert (diagnostic indications are not restricted by current regulations)..-(b) deviations-from the manufacturer's instructions,in-preparing'radiopharmaceuticals, i

and.(c). compounding radiopharmaceuticals from reagent chemicals.-

l l

The NRC published a Federal Register notice (54 FR 38239.- September 15,

H 1989), announcing receipt of the petition and providing a 90-day public comment period. We have" received more than 400 comment letters..

In light of the information submitted by the. petitioners and-the comenters, the.NRC is currently reexamining its. regulations governing the-use of radiopharmaceuticals intnuclear medicine. The issues raised will-be addressed in a rulemaking proceeding specifically' designed to resolve the petition. During this rulemaking process, the NRC will consult with-the Food and Drug. Administration', which approves the package inserts and q

l the manufacturer's-instructions,.and the' State Boards of Pharmacy:and invite their views regarding the resolution of this' petition U

t' I want to assure you-that the comments of your constituent will;be considered along with the others in reexamining our. regulations. _However,-

y it would be premature to predict the outcome.of the reexamination before' t

completion of the rulemaking proceeding -

i I trust this information 'is responsive to your request..

l Sincerely',

3

.l FUtt 7pg7ASCll SCAN Dennis.K. Rathbun D ctor Congressional Aff irs Office of Gover ntal and 1

4 l

Public Affairs CCd d

g20go3909337 35-9

,l PDC m

m

~ '..

(>

, f-r i

N.

1 l

u

)

s

,r w.e j

4 l

I i

l l

i

. \\

4 t'

(

i e

- )

i i

4' Letter also verbally approved by. Jim Blaha and Mike Weber (per Dennis Rathbun/Betsy Keeling) p /-//- 90 j

1 Y

w -

m

_.....,.,,,,,,,,,,,,,,..r,.,,,m.......,,,

,7,,.,..,.,,#,..

-m...,,,,